Big Cypress Acquisition Corp.
Completed
Follow
Detailed Information
Information on this SPAC.
- Sponsors
- IPO Size
- $100M
- Underwriters
- Focus
- Life Sciences
- SEC Filings
- 1833214
- Public Embarc Page
- https://embarc.com/capital/spac/1833214/BCYP/big-cypress-acquisition
- IPO Ticker
- BCYP
SPAC Leadership
Information on the SPAC leadership.
- Chief Executive Officer, Chief Financial Officer and DirectorSamuel J. Reich
- Non-Executive Chairman of the BoardJeffrey G. Spragens
- DirectorJames J. Martin
- DirectorStephen D. Collins, MD, PhD.
- DirectorIlan Katz
- DirectorJames Martin
Target Information
Information on the SPAC target for merger.
- Company
- SAB Biotherapeutics
- Presentation
- Investor Presentation (SEC) on 2021-06-22
- Description
- SAB Biotherapeutics is "a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces targeted, high potency, fully-human polyclonal antibodies at scale."